Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Celiprolol for Vascular Ehlers-Danlos Syndrome (BBEST)
NCT00190411Phase 4Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Oct 2003
- Primary completion
- Apr 2011
- Modality
- Small Molecules
01
Overview
Phase 4, randomised, open-label trial of celiprolol in Vascular Ehlers-Danlos syndrome (VEDS) (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Reduction in the rate of major cardiovascular events at 5 years. Started Oct 2003; status: completed.
02
Drugs
celiprolol
03
Conditions
Vascular Ehlers-Danlos syndrome (VEDS)
Beyond the preview
Go deeper on NCT00190411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00190411.